Prescription Drug Abuse (R21) | Apply Online

FAQs: Prescription Drug Abuse (R21) (PA-16-232)

What is the Prescription Drug Abuse (R21) funding opportunity (PA-16-232)?

PA-16-232 is a discretionary NIH grant funding opportunity under HHS/NIH (listed as HHS-NIH11) using the R21 mechanism. It supports innovative, early-stage (exploratory and developmental) research focused on improving understanding of prescription drug abuse and advancing practical ways to prevent and treat it.

What is the main purpose of this FOA?

The FOA aims to generate new knowledge about why prescription drug abuse happens, who is most affected, what harms result from misuse, and what prevention strategies, service delivery models, and treatments (behavioral and pharmacological) work best. It emphasizes moving beyond documenting the problem toward actionable solutions that can be tested, refined, and eventually scaled.

Is this opportunity limited to describing the scope of prescription drug abuse?

No. While defining the scope and characterizing patterns of misuse are included, the FOA also emphasizes prevention, service delivery approaches, and treatment strategies, with the goal of producing actionable evidence and solution-oriented research.

What kinds of research approaches does NIH encourage under this FOA?

The FOA encourages breadth in methods and topics, including basic science research (mechanisms and risk processes), clinical studies (patient behaviors, outcomes, and interventions), epidemiological research (prevalence, incidence, and population patterns), and health services research (how healthcare delivery, policy, and system design influence misuse and outcomes).

What topics or questions are within scope?

Within scope are studies that examine drivers, pathways, and consequences of prescription drug abuse; identify affected groups; assess harms of misuse; and evaluate what prevention strategies, service delivery models, and treatments work best. Projects may also focus on how misuse varies by drug class, by combinations of substances used together (polydrug use), and by pathways from appropriate medical exposure to nonmedical use, misuse, or addiction.

Does the FOA support research on real-world patterns like polydrug use?

Yes. The FOA explicitly supports research reflecting real-world patterns, including polydrug use and combinations of medication types, recognizing that these combinations can increase overdose risk and complicate treatment.

Which prescription drug classes are covered by this FOA?

The scope covers major classes of prescription drugs with high abuse liability, including prescription opioids and other analgesics, stimulants prescribed for attention-related disorders, sedative/hypnotics used for sleep conditions, and anxiolytics used for anxiety and related disorders.

Can research connect misuse to the condition the medication was originally prescribed for?

Yes. The FOA encourages research that links medications to their original clinical indications (such as pain, sleep disorders, anxiety disorders, or obesity) and examines how environmental context and individual vulnerabilities contribute to misuse.

Does the FOA address transitions from legitimate use to misuse or addiction?

Yes. A key theme is understanding pathways and transitions from clinically appropriate prescribing and use to increased risk, including shifts to misuse, diversion, dependence, or addiction.

What populations and differences does NIH encourage applicants to study?

Applicants are encouraged to analyze differences across age groups, race and ethnicity, gender, and psychiatric symptom profiles, with recognition that prescription drug abuse often intersects with mental health conditions, trauma histories, and other social determinants of health.

Does the FOA encourage studying mental health and psychiatric symptom profiles?

Yes. The announcement specifically notes intersections with mental health conditions and invites analysis of psychiatric symptom profiles as part of understanding who is impacted and why.

What levels of risk and protective factors are emphasized?

The FOA highlights multi-level risk and protective factors, including individual/patient-level factors (for example pain severity, mental health symptoms, prior substance use, coping styles), prescriber-level factors (prescribing practices, decision-making, monitoring behaviors, adherence to guidelines), and health system-level factors (access to care, care coordination, insurance design, use of prescription drug monitoring programs, and clinical workflow constraints).

Are prescriber practices and monitoring behaviors within scope?

Yes. Prescriber-level factors such as prescribing practices, decision-making, monitoring behaviors, and adherence to guidelines are explicitly included as areas of interest.

Are health system design and policy factors within scope?

Yes. The FOA encourages health services research and specifically references system-level issues such as access to care, care coordination, insurance design, prescription drug monitoring program use, and workflow constraints.

What grant mechanism is used, and what does it imply?

This opportunity uses the NIH R21 mechanism, which typically supports exploratory and developmental projects that may be earlier-stage but are intended to be innovative and high-impact.

What is the maximum award amount listed for this opportunity?

The maximum award amount (award ceiling) listed is $200,000.

Who is eligible to apply?

Eligibility is broad and includes state, county, and local governments; public and private institutions of higher education; independent school districts; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including entities other than small businesses); small businesses; and other organizations as allowed under the eligibility clarification language.

Are for-profit organizations and small businesses eligible?

Yes. For-profit organizations (including entities other than small businesses) and small businesses are both listed as eligible applicants.

Are tribal governments and tribal organizations eligible?

Yes. Federally recognized tribal governments and other tribal organizations are explicitly listed among eligible applicants.

When was the FOA posted, and what was the closing date?

The FOA was posted on May 23, 2016, and the closing date listed is May 7, 2019.

Which agency is offering this funding opportunity?

This funding opportunity is offered by HHS/NIH (listed as HHS-NIH11).

What CFDA number is associated with this program?

The opportunity is associated with CFDA number 93.279 (also listed as 93.279 in the source data).

What is the overall emphasis or theme of the FOA?

The FOA is oriented toward catalyzing creative, methodologically diverse research that clarifies drivers and consequences of prescription drug abuse and produces actionable evidence on prevention, service delivery, and treatment strategies. It frames prescription drug abuse as a multi-layered public health issue influenced by patients, clinicians, healthcare systems, and broader social environments.